Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN) on Jan. 15 announced it has agreed to sell $20 million of units in a registered direct offering at a price of $1.05 per unit. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock opened at $1.03 in last session, and closed at $0.950, while the day range of RNN stock is $0.91 $1.04. The stock showed a negative weekly performance of -8.65 %.
Cleveland BioLabs, Inc. (NASDAQ:CBLI) On January 23, 2014, issued a press release announcing that the Biomedical Advanced Research and Development Authority had terminated negotiations related to the Company’s proposal for further development of Entolimod as a medical radiation countermeasure. Cleveland BioLabs, Inc. (NASDAQ:CBLI) stock opened at $0.64, in last session and closed at $0.750, by losing -33.63%. The 52 week range of $0.63 – $0.28. Company’s market capitalization is $33.89 million.
Vical Incorporated (NASDAQ:VICL) was a big mover last session, as its shares rose almost 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the healthcare company, as the stock is now up over 35% in the past one-month time frame. Vical Incorporated (NASDAQ:VICL) stock decreased -7.56% and finished the last session at $1.59. The EPS of the stock remained -0.42. Company’s market capitalization is $137.98 million.
Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, announced the publication of a study supporting the potential role of the suppression of Toll-like-receptors (TLRs) 7, 8, and 9 in the treatment of psoriasis. Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock opened the session at $4.29, and closed the session at $4.14. The 52 week range of the IDRA stock remained $0.19 – $5.55 and the day range was $3.95 – $4.35.